Title : Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib.

Pub. Date : 2010 Feb

PMID : 20139391






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib. Dasatinib ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens
2 BACKGROUND: Dasatinib 100 mg once daily achieves intermittent BCR-ABL kinase inhibition and is approved for chronic-phase chronic myeloid leukemia patients resistant or intolerant to imatinib. Dasatinib ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens